Tag: CK-101

March 13, 2019

Checkpoint Therapeutics Announces Issuance of Two New Patents for EGFR Inhibitor CK-101

Checkpoint Therapeutics (NASDAQ:CKPT) has announced that the European Patent Office (EPO) has issued a composition of matter patent for the...
September 7, 2018

Checkpoint Therapeutics’ Share Price Dips on Preliminary Results

Checkpoint Therapeutics released preliminary results for its clinical trial on Thursday, but investors are not sharing the enthusiasm.
September 6, 2018

Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients...